Loading…

Azithromycin alters macrophage phenotype

Objectives To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods J774 ce...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2008-03, Vol.61 (3), p.554-560
Main Authors: Murphy, Brian S., Sundareshan, Vidya, Cory, Theodore J., Hayes, Don, Anstead, Michael I., Feola, David J.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c477t-ea2f1f6ff58108049be810da7d11a8a711f63ed42ec9a2ff9c4f946eb825964a3
cites
container_end_page 560
container_issue 3
container_start_page 554
container_title Journal of antimicrobial chemotherapy
container_volume 61
creator Murphy, Brian S.
Sundareshan, Vidya
Cory, Theodore J.
Hayes, Don
Anstead, Michael I.
Feola, David J.
description Objectives To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.
doi_str_mv 10.1093/jac/dkn007
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70307399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkn007</oup_id><sourcerecordid>70307399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-ea2f1f6ff58108049be810da7d11a8a711f63ed42ec9a2ff9c4f946eb825964a3</originalsourceid><addsrcrecordid>eNqF0MtKAzEUBuAgiq2XjQ8gRVBEGHuSzCSTpYg3rLhRFDchzSR22rmZzID16Y22WHChqxzIxzn8P0J7GE4xCDqcKj3MZhUAX0N9HDOICAi8jvpAIYl4nNAe2vJ-CgAsYekm6uGUUGAp66Pjs4-8nbi6nOu8GqiiNc4PSqVd3UzUqxk0E1PV7bwxO2jDqsKb3eW7jR4vLx7Or6PR_dXN-dko0jHnbWQUsdgya5MUQwqxGJswZIpnGKtUcRw-qcliYrQI1AodWxEzM05JIlis6DY6WuxtXP3WGd_KMvfaFIWqTN15yUMoToX4FxJIKMMUB3jwC07rzlUhhCSYMw7wjU4WKCT33hkrG5eXys0lBvnVsgwty0XLAe8vN3bj0mQruqw1gMMlUF6rwjpV6dz_OAKYEUH5ytVd8_fBaOFy35r3H6ncTDJOeSKvn1_k0-gWRrfsTjL6CeW8n6U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217670031</pqid></control><display><type>article</type><title>Azithromycin alters macrophage phenotype</title><source>Oxford Journals Online</source><creator>Murphy, Brian S. ; Sundareshan, Vidya ; Cory, Theodore J. ; Hayes, Don ; Anstead, Michael I. ; Feola, David J.</creator><creatorcontrib>Murphy, Brian S. ; Sundareshan, Vidya ; Cory, Theodore J. ; Hayes, Don ; Anstead, Michael I. ; Feola, David J.</creatorcontrib><description>Objectives To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkn007</identifier><identifier>PMID: 18230686</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Azithromycin - pharmacology ; Biological and medical sciences ; Cell Line ; Cell Line, Transformed ; Cellular biology ; Chemotherapy ; cystic fibrosis ; Cytokines - biosynthesis ; Cytokines - genetics ; Errors of metabolism ; Genotype &amp; phenotype ; Immune system ; Immunophenotyping ; inflammation ; macrolides ; Macrophages - classification ; Macrophages - drug effects ; Macrophages - immunology ; Macrophages - metabolism ; Medical sciences ; Metabolic diseases ; Mice ; Mice, Inbred BALB C ; Miscellaneous hereditary metabolic disorders ; Pharmacology. Drug treatments</subject><ispartof>Journal of antimicrobial chemotherapy, 2008-03, Vol.61 (3), p.554-560</ispartof><rights>The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2008</rights><rights>2008 INIST-CNRS</rights><rights>The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-ea2f1f6ff58108049be810da7d11a8a711f63ed42ec9a2ff9c4f946eb825964a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20162937$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18230686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murphy, Brian S.</creatorcontrib><creatorcontrib>Sundareshan, Vidya</creatorcontrib><creatorcontrib>Cory, Theodore J.</creatorcontrib><creatorcontrib>Hayes, Don</creatorcontrib><creatorcontrib>Anstead, Michael I.</creatorcontrib><creatorcontrib>Feola, David J.</creatorcontrib><title>Azithromycin alters macrophage phenotype</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Objectives To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.</description><subject>Animals</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Azithromycin - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Cell Line, Transformed</subject><subject>Cellular biology</subject><subject>Chemotherapy</subject><subject>cystic fibrosis</subject><subject>Cytokines - biosynthesis</subject><subject>Cytokines - genetics</subject><subject>Errors of metabolism</subject><subject>Genotype &amp; phenotype</subject><subject>Immune system</subject><subject>Immunophenotyping</subject><subject>inflammation</subject><subject>macrolides</subject><subject>Macrophages - classification</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - immunology</subject><subject>Macrophages - metabolism</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Miscellaneous hereditary metabolic disorders</subject><subject>Pharmacology. Drug treatments</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqF0MtKAzEUBuAgiq2XjQ8gRVBEGHuSzCSTpYg3rLhRFDchzSR22rmZzID16Y22WHChqxzIxzn8P0J7GE4xCDqcKj3MZhUAX0N9HDOICAi8jvpAIYl4nNAe2vJ-CgAsYekm6uGUUGAp66Pjs4-8nbi6nOu8GqiiNc4PSqVd3UzUqxk0E1PV7bwxO2jDqsKb3eW7jR4vLx7Or6PR_dXN-dko0jHnbWQUsdgya5MUQwqxGJswZIpnGKtUcRw-qcliYrQI1AodWxEzM05JIlis6DY6WuxtXP3WGd_KMvfaFIWqTN15yUMoToX4FxJIKMMUB3jwC07rzlUhhCSYMw7wjU4WKCT33hkrG5eXys0lBvnVsgwty0XLAe8vN3bj0mQruqw1gMMlUF6rwjpV6dz_OAKYEUH5ytVd8_fBaOFy35r3H6ncTDJOeSKvn1_k0-gWRrfsTjL6CeW8n6U</recordid><startdate>20080301</startdate><enddate>20080301</enddate><creator>Murphy, Brian S.</creator><creator>Sundareshan, Vidya</creator><creator>Cory, Theodore J.</creator><creator>Hayes, Don</creator><creator>Anstead, Michael I.</creator><creator>Feola, David J.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7T5</scope><scope>7X8</scope></search><sort><creationdate>20080301</creationdate><title>Azithromycin alters macrophage phenotype</title><author>Murphy, Brian S. ; Sundareshan, Vidya ; Cory, Theodore J. ; Hayes, Don ; Anstead, Michael I. ; Feola, David J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-ea2f1f6ff58108049be810da7d11a8a711f63ed42ec9a2ff9c4f946eb825964a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Azithromycin - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Cell Line, Transformed</topic><topic>Cellular biology</topic><topic>Chemotherapy</topic><topic>cystic fibrosis</topic><topic>Cytokines - biosynthesis</topic><topic>Cytokines - genetics</topic><topic>Errors of metabolism</topic><topic>Genotype &amp; phenotype</topic><topic>Immune system</topic><topic>Immunophenotyping</topic><topic>inflammation</topic><topic>macrolides</topic><topic>Macrophages - classification</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - immunology</topic><topic>Macrophages - metabolism</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Miscellaneous hereditary metabolic disorders</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murphy, Brian S.</creatorcontrib><creatorcontrib>Sundareshan, Vidya</creatorcontrib><creatorcontrib>Cory, Theodore J.</creatorcontrib><creatorcontrib>Hayes, Don</creatorcontrib><creatorcontrib>Anstead, Michael I.</creatorcontrib><creatorcontrib>Feola, David J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Immunology Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murphy, Brian S.</au><au>Sundareshan, Vidya</au><au>Cory, Theodore J.</au><au>Hayes, Don</au><au>Anstead, Michael I.</au><au>Feola, David J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Azithromycin alters macrophage phenotype</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2008-03-01</date><risdate>2008</risdate><volume>61</volume><issue>3</issue><spage>554</spage><epage>560</epage><pages>554-560</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Objectives To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18230686</pmid><doi>10.1093/jac/dkn007</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2008-03, Vol.61 (3), p.554-560
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_70307399
source Oxford Journals Online
subjects Animals
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Azithromycin - pharmacology
Biological and medical sciences
Cell Line
Cell Line, Transformed
Cellular biology
Chemotherapy
cystic fibrosis
Cytokines - biosynthesis
Cytokines - genetics
Errors of metabolism
Genotype & phenotype
Immune system
Immunophenotyping
inflammation
macrolides
Macrophages - classification
Macrophages - drug effects
Macrophages - immunology
Macrophages - metabolism
Medical sciences
Metabolic diseases
Mice
Mice, Inbred BALB C
Miscellaneous hereditary metabolic disorders
Pharmacology. Drug treatments
title Azithromycin alters macrophage phenotype
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A02%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Azithromycin%20alters%20macrophage%20phenotype&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Murphy,%20Brian%20S.&rft.date=2008-03-01&rft.volume=61&rft.issue=3&rft.spage=554&rft.epage=560&rft.pages=554-560&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkn007&rft_dat=%3Cproquest_cross%3E70307399%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c477t-ea2f1f6ff58108049be810da7d11a8a711f63ed42ec9a2ff9c4f946eb825964a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=217670031&rft_id=info:pmid/18230686&rft_oup_id=10.1093/jac/dkn007&rfr_iscdi=true